Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

0 new patients are infected each year. It is estimated that 10,000 to 12,000 patients die annually in the United States from complications resulting from HCV infection. The current standard of care for treating chronic hepatitis C is combination therapy consisting of pegylated alpha interferon and ribavirin.

About Diabetes

Diabetes affects more than 20 million in the United States and an estimated 194 million adults worldwide. Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States. According to the U.S. Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve target A1c levels with their current treatment regimen.

DUROS is a registered trademark of ALZA Corporation (Mountain View, CA) licensed to Intarcia Therapeutics, Inc. Intarcia and its logo are trademarks of Intarcia Therapeutics, Inc. (Emeryville, CA).

CONTACT: James Ahlers, Chief Financial Officer of Intarcia Therapeutics,+1-510-652-2600, ext 235

Web site: http://www.intarcia.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:5/15/2008)...ared device to identify the, lipid core (fatty) c...th complications of coronary ste...InfraReDx, Inc. today,announced that physicians at...ssfully used its LipiScan(TM) Coronary Imaging Sys...ion. This is the first patient in the,world in who...
(Date:5/15/2008)...-- Tigris Pharmaceuticals,Inc. announced today th...ent Agreement (CRADA) with the National Cancer Ins...nical development of AFP-464, an,aminoflavone curr... to,metabolites which bind covalently to DNA, resu...art of a four-year CRADA encompassing multiple Pha...
(Date:5/15/2008)...data reports in third quarter ...e-FirstCall/ -- VIA Pharmaceuticals,Inc. (Nasdaq:...evelopment of,compounds for the treatment of cardi...pleted patient enrollment in its acute coronary sy...Phase 2 trials investigating VIA-2291,the company...
(Date:5/14/2008)...rstCall/ -- Progen,Pharmaceuticals Limited (ASX:PG...has resumed patient enrolment in the phase 1 dose-...e analogue, PG-11047 (formerly CGC-11047),for pati...development of PG-11047 - the lead clinical,compou...its acquisition of,Cellgate, Inc earlier this year...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2Record Attendance at the 2007 National Ergonomics Conference and Exposition 1474 1Record Attendance at the 2007 National Ergonomics Conference and Exposition 1474 2Brookdale Senior Living Announces Enhanced Web Site 7694 1Brookdale Senior Living Announces Enhanced Web Site 7694 2National Federation of the Blind to Award 24100 000 7690 1National Federation of the Blind to Award 24100 000 7690 2HEI Inc Files Form 15 to Voluntarily Deregister its Shares With the SEC 7686 1HEI Inc Files Form 15 to Voluntarily Deregister its Shares With the SEC 7686 2HEI Inc Files Form 15 to Voluntarily Deregister its Shares With the SEC 7686 3
...,Lakeridge Healths large multi-site lab faced cha... accreditation management challenges which were e...umes. The lab realized that better document contro...lso to enable their laboratorians to more efficien...sessed a variety of Quality Management software pa...
...Contributing Editor , ,Medical conventions ar...he effectiveness of cold medicine and the gold sta...ged. Standards in cholesterol testing are the late..., cholesterol has been measured by a simple panel ...nd low-density lipoprotein cholesterol (LDL-C); go...
Other Medicine Technology:Choosing Lab Quality Management Software 2Choosing Lab Quality Management Software 3Choosing Lab Quality Management Software 4Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal 2Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal 3
(Date:5/16/2008)...on abstracts or poster presentations at the annual...ogy (ASCO) to be held in Chicago, Illinois, May 30... Early Detection of Malignant Pleural Mesothelioma...arly detection and prognostic marker,in malignant...ey Pass, M.D., professor of cardiothoracic surgery...
(Date:5/16/2008)...promising drug formerly approved as a second line ...nhanced the effectiveness of hormonal therapy for ...st cancer, according to a Phase II clinical trial .... Anderson Cancer Center. , These findings are s...or Iressa in breast cancer, as well as for the ent...
(Date:5/16/2008)...ire-USNewswire/ -- RediStat,Corporation announced ...ency messaging services to its healthcare clients....king video communications service in,conjunction w... were made,by RediStat President, Michael Hemlepp,...ing held in Ft. Lauderdale., "We are very pleased...
(Date:5/16/2008).../ -- Tao Formulations announces the,official launc...e Internal,Medicine 2008 conference in Washington ...of years of research to develop a safe, all-natura...lieving menopausal symptoms., Company founder and...n,and gynecologist, founded Tao Formulations (htt...
Breaking Medicine News(10 mins):Health News:NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO 2Health News:NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO 3Health News:NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO 4Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 2Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 3Health News:RediStat Corporation Partners With ALERT FM for Disaster-Proof Emergency Communications 2Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2
... around the world are gathering in the West Africa...ed to claim 1,00,000 African lives every year. Po... as 'African Trypanosomiasis', the disease is carr...ing in Tsetse fly-endemic areas of west and centra...
..., a highly addictive stimulant drug, whose abuse h...he world, causes long-term changes in the human br...otor coordination, according to a study published ...s found that these effects are seen even in metham...
...s like it could be making healthy people with no h...prescribed to more than 38 million people world-wi...ies biggest success stories of recent years. Proza... SSRIs (selective serotonin reuptake inhibitors). ...
...new survey, it is found that doctors are prescribi...e throat is the second most common symptom sending...s caused by a virus and will not respond to antibi...ospital and the Stanford Center for Research in Di...
Other Medicine News:Health News:Drug abuse leads to long standing changes in the brain 2Health News:Drug abuse leads to long standing changes in the brain 3Health News:Wonder drug - could end in disaster 2
Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 150)
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box.
Designed for explanation of foldable intraocular lenses. The instrument consists of a grooved platform that is placed under the implant and divides the implant into two pieces. The lower platform hel
Shafts angled 8 mm from tip to bend with smooth jaws. Flat, cross action handle with holes and dull finish.
Medicine Products: